Vaxxinity, Inc.
🇺🇸United States
Clinical Trials
4
Active:2
Completed:1
Trial Phases
3 Phases
Phase 1:2
Phase 2:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (50.0%)Phase 2
1 (25.0%)Phase 3
1 (25.0%)A Study to Investigate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 Administered IM in Adult Participants
Phase 1
Active, not recruiting
- Conditions
- Hypercholesterolemia
- Interventions
- Biological: Placebo
- First Posted Date
- 2023-03-09
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Vaxxinity, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT05762276
- Locations
- 🇦🇺
Northern Beaches Clinical Research, Brookvale, New South Wales, Australia
🇦🇺Sutherland Shire Clinical Research, Miranda, New South Wales, Australia
🇦🇺Emeritus Research, Melbourne, Victoria, Australia
A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Vaxxinity, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05477095
- Locations
- 🇧🇪
Katholieke Universiteit Leuven, Leuven, Belgium
Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine
Phase 3
Active, not recruiting
- Conditions
- COVID-19 Vaccines
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2022-10-14
- Lead Sponsor
- Vaxxinity, Inc.
- Target Recruit Count
- 944
- Registration Number
- NCT05293665
- Locations
- 🇺🇸
PanAmerican Clinical Research, Brownsville, Texas, United States
🇵🇦Cevaxin David, David, Panama
🇵🇦Cevaxin 24 de Dieciembre, Panamá, Panama
A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine
Phase 2
Withdrawn
- Conditions
- Covid-19SARS-CoV-2Coronavirus
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Vaxxinity, Inc.
- Registration Number
- NCT04683224
News
AC Immune's ACI-7104 Shows Promise in Phase II Parkinson's Disease Trial
AC Immune's stock surged by over 20% following positive interim data from its Phase II VacSYn trial of ACI-7104.056 for Parkinson's disease.